Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

How does all-trans retinoic acid and arsenic trioxide treatment affect the long-term quality of life of patients with acute promyelocytic leukemia?

Posted by on Oct 17, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the treatment effects of all-trans retinoic acid (ATRA; Vesanoid) and arsenic trioxide (ATO; Trisenox), compared to ATRA with standard chemotherapy on long-term health-related quality of life (HRQoL) in patients with acute promyelocytic leukemia (APL). The data showed better long-term HRQoL measures in patients treated...

Read More

Evaluating minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia 

Evaluating minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia 

Posted by on Oct 16, 2021 in Leukemia | 0 comments

In a nutshell This review aimed to investigate the prognostic value of minimal residual disease (MRD) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).  This review concluded that MRD is a good predictor of outcomes in these patients.   Some background Ph+ ALL is an aggressive type of...

Read More

Evaluating blood vessel-related side effects of long-term use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Evaluating blood vessel-related side effects of long-term use of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Posted by on Oct 3, 2021 in Leukemia | 0 comments

In a nutshell This study examined the association between long-term use of three different tyrosine kinase inhibitors (TKIs) and the occurrence of vascular (blood vessel) adverse events (side effects; VAEs) in patients with chronic myeloid leukemia (CML). The data showed a possibly higher risk of developing VAEs when patients with CML were...

Read More

Comparing enasidenib to current standard of care therapies for patients with relapsed/refractory acute myeloid leukemia and IDH2 mutations

Comparing enasidenib to current standard of care therapies for patients with relapsed/refractory acute myeloid leukemia and IDH2 mutations

Posted by on Sep 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare enasidenib (Idhifa) to current standard of care therapies for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoietic stem cell transplantation (HSCT).  This study concluded that enasidenib significantly...

Read More

Real-world effectiveness of combining arsenic trioxide with all-trans retinoic acid in patients with acute promyelocytic leukemia.

Real-world effectiveness of combining arsenic trioxide with all-trans retinoic acid in patients with acute promyelocytic leukemia.

Posted by on Sep 26, 2021 in Leukemia | 0 comments

In a nutshell This study described the real-world effectiveness and safety of arsenic trioxide (ATO; Trisenox) combined with all-trans retinoic acid (ATRA; Vesanoid), without chemotherapy, in patients with newly diagnosed acute promyelocytic leukemia (APL). The authors concluded that a combination of ATO and ATRA showed good results for the...

Read More

Does reduced intensity conditioning hematopoietic stem cell transplantation improve the outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation?

Does reduced intensity conditioning hematopoietic stem cell transplantation improve the outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation?

Posted by on Sep 19, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate whether reduced-intensity conditioning (RIC) hemopoietic stem cell transplantation (HSCT) improves the outcomes of patients with chronic lymphocytic leukemia (CLL) with and without Richter's transformation (RT).  This study concluded that this treatment may be suitable in early...

Read More

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Posted by on Sep 16, 2021 in Leukemia | 0 comments

In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...

Read More

Long term outcomes and risk factors for patients with advanced chronic myeloid leukemia who have undergone allogeneic stem cell transplantation

Long term outcomes and risk factors for patients with advanced chronic myeloid leukemia who have undergone allogeneic stem cell transplantation

Posted by on Sep 5, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to determine the long-term outcomes and risk factors after allogeneic stem cell transplantation (allo-SCT) for patients with advanced phase chronic myeloid leukemia (CML).  This study concluded that allo-SCT improved the outcomes of these patients, particularly in those with donors younger than 36...

Read More

Comparing effectiveness and safety of acalabrutinib and ibrutinib in patients previously treated for chronic lymphocytic leukemia.

Comparing effectiveness and safety of acalabrutinib and ibrutinib in patients previously treated for chronic lymphocytic leukemia.

Posted by on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study compared acalabrutinib (Calquence) and ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL). The data showed that both drugs had similar effectiveness while acalabrutinib showed fewer cardiovascular side effects compared to ibrutinib. Some background Chronic lymphocytic...

Read More

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Effects of nilotinib on height and safety in children with chronic myeloid leukemia.

Posted by on Aug 29, 2021 in Leukemia | 0 comments

In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...

Read More